These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 37239941)

  • 1. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.
    Brandi N; Renzulli M
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
    Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC.
    Biondetti P; Saggiante L; Ierardi AM; Iavarone M; Sangiovanni A; Pesapane F; Fumarola EM; Lampertico P; Carrafiello G
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
    Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
    BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy.
    Duan Y; Zhang H; Tan T; Ye W; Yin K; Yu Y; Kang M; Yang J; Liao R
    Biosci Trends; 2024 Jan; 17(6):427-444. PubMed ID: 37981319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective.
    Kim GH; Kim JH; Kim PH; Chu HH; Gwon DI; Ko HK
    Korean J Radiol; 2021 Nov; 22(11):1822-1833. PubMed ID: 34431250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
    Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
    Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities.
    da Fonseca LG; Araujo RLC
    World J Gastroenterol; 2022 Jul; 28(28):3573-3585. PubMed ID: 36161045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments.
    Della Corte A; Rimini M; Steidler S; Palumbo D; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A; De Cobelli F
    Cardiovasc Intervent Radiol; 2023 Feb; 46(2):175-186. PubMed ID: 36478027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress.
    Brown ZJ; Hewitt DB; Pawlik TM
    Expert Opin Investig Drugs; 2022 Apr; 31(4):379-391. PubMed ID: 34788184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape.
    Young S; Hannallah J; Goldberg D; Sanghvi T; Arshad J; Scott A; Woodhead G
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
    Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined locoregional-immunotherapy for liver cancer.
    Greten TF; Mauda-Havakuk M; Heinrich B; Korangy F; Wood BJ
    J Hepatol; 2019 May; 70(5):999-1007. PubMed ID: 30738077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.
    Liu H; Wang C; Wang R; Cao H; Cao Y; Huang T; Lu Z; Xiao H; Hu M; Wang H; Zhao J
    Chin J Cancer Res; 2024 Apr; 36(2):167-194. PubMed ID: 38751435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy.
    Qiao W; Wang Q; Hu C; Zhang Y; Li J; Sun Y; Yuan C; Wang W; Liu B; Zhang Y
    Front Immunol; 2022; 13():1019772. PubMed ID: 36389724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locoregional Therapies in the Treatment of 3- to 5-cm Hepatocellular Carcinoma: Critical Review of the Literature.
    Young S; Golzarian J
    AJR Am J Roentgenol; 2020 Jul; 215(1):223-234. PubMed ID: 32255691
    [No Abstract]   [Full Text] [Related]  

  • 18. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?
    Boilève J; Guimas V; David A; Bailly C; Touchefeu Y
    Curr Oncol; 2024 May; 31(6):3199-3211. PubMed ID: 38920726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of locoregional therapies in the wake of systemic therapy.
    Palmer DH; Malagari K; Kulik LM
    J Hepatol; 2020 Feb; 72(2):277-287. PubMed ID: 31954492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
    Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
    Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.